```html

Ureidoglycolate Hydrolase Deficiency (Uric Acid Metabolism Disorder)

Overview

Ureidoglycolate hydrolase deficiency (also called Uricase (Uox) deficiency or Uric acid metabolism disorder) is an extremely rare inherited metabolic disorder that impairs the body’s ability to break down uric acid, a waste product formed from the normal turnover of purines (the building blocks of DNA and RNA). When the enzyme ureidoglycolate hydrolase is deficient or absent, uric acid accumulates in the blood and tissues, leading to a spectrum of clinical problems.

• Who it affects: Autosomal recessive inheritance means that the condition usually appears in children of consanguineous parents, though sporadic cases have been reported.
• Prevalence: Fewer than 150 cases have been published worldwide as of 2023, giving an estimated prevalence of < 1 per 1 million people [1].
• Age of presentation: Symptoms typically begin in infancy or early childhood, but mild forms may not be recognized until adolescence or adulthood.

Symptoms

Because uric acid builds up systemically, patients may experience a mixture of renal, musculoskeletal, dermatologic, and neurologic signs. The severity depends on residual enzyme activity.

Renal manifestations

• Nephrolithiasis (kidney stones): Small, radiopaque stones composed of uric acid can cause flank pain, hematuria, and urinary obstruction.
• Acute kidney injury (AKI): Crystallization of uric acid in renal tubules can lead to sudden loss of kidney function.
• Chronic kidney disease (CKD): Progressive loss of glomerular filtration rate (GFR) due to chronic interstitial inflammation.

Musculoskeletal

• Gouty arthritis: Deposition of monosodium urate crystals in joints, causing sudden, severe pain, swelling, and redness.
• Tophi: Chalky deposits under the skin, especially around ears, fingers, and toes.
• Growth retardation: Chronic metabolic imbalance can impair linear growth in children.

Dermatologic & systemic

• Uric acid skin rash: Pruritic, erythematous patches often mistaken for eczema.
• Fatigue & malaise: Nonspecific but common, especially during gout flares.

Neurologic (rare)

• Seizures or developmental delay have been reported in a few neonatal‑onset cases, likely secondary to severe metabolic derangement.

Causes and Risk Factors

The disorder results from mutations in the UOX gene located on chromosome 3p26.3. Over 20 pathogenic variants have been identified, including missense, nonsense, and splice‑site mutations that produce a non‑functional enzyme.

Genetic cause

• Autosomal recessive inheritance: Both parents must carry a defective copy.
• Consanguinity: Increases the chance of inheriting two defective alleles (reported in >40 % of published families) [2].

Additional risk modifiers

• High purine diet: Excessive intake of red meat, seafood, organ meats, and legumes can worsen hyperuricemia.
• Dehydration: Low urine volume favors uric acid crystallization.
• Obesity and metabolic syndrome: These conditions independently raise serum urate levels, compounding the genetic defect.

Diagnosis

Because the clinical picture overlaps with more common gout and kidney‑stone disorders, a high index of suspicion is essential when hyperuricemia appears in children or in families with a history of early‑onset gout.

Laboratory tests

• Serum uric acid: Often markedly elevated (>10 mg/dL in adults; >8 mg/dL in children) [3].
• Urine uric acid excretion: Paradoxically low or normal despite high serum levels because the enzyme block prevents further metabolism.
• Renal function panel: Creatinine, BUN, eGFR to assess kidney involvement.
• Genetic testing: Sequencing of the UOX gene confirms the diagnosis; whole‑exome sequencing is increasingly used for undiagnosed hyperuricemia.

Imaging

• Renal ultrasound: Detects stones, hydronephrosis, or medullary nephrocalcinosis.
• Dual‑energy CT (DECT): Can differentiate uric‑acid crystals from calcium‑based stones.
• Joint ultrasound: Shows tophaceous deposits and gouty effusions.

Diagnostic criteria (proposed)

1. Persistent hyperuricemia (> 8 mg/dL) not explained by diet, medications, or other diseases.
2. Evidence of renal or gouty manifestations before age 30.
3. Identification of biallelic pathogenic UOX variants.

Treatment Options

Management aims to lower serum urate, prevent crystal formation, and protect renal function. Because the defect is genetic, therapy is lifelong.

Pharmacologic therapy

• Xanthine oxidase inhibitors (XOIs):
  • Allopurinol (initial 100 mg daily, titrated to 300‑600 mg) reduces uric acid production.
  • Febuxostat (40‑80 mg daily) is an alternative for allopurinol‑intolerant patients.
  *Both require dose adjustment in CKD and careful monitoring for hypersensitivity.
• Uricosuric agents:
  • Probenecid (500 mg twice daily) increases renal excretion of urate; contraindicated in advanced CKD.
  • Lesinurad (200‑400 mg) used in combination with an XOI; monitor for renal adverse events.
• Uricase therapy (recombinant uricase):
  • Pegloticase IV infusion (8 mg every 2 weeks) converts uric acid to soluble allantoin.
  • Indicated for refractory disease; risk of infusion reactions and development of anti‑drug antibodies (≈30 %).
• Anti‑inflammatory agents for gout flares: NSAIDs, colchicine, or corticosteroids as per gout guidelines.

Procedural interventions

• Kidney stone removal: Shockwave lithotripsy, ureteroscopy, or percutaneous nephrolithotomy depending on stone size.
• Renal replacement therapy: Dialysis may be required in severe AKI; it does not correct the metabolic defect.

Lifestyle modifications

• Low‑purine diet: limit red meat, organ meats, anchovies, sardines, and high‑fructose corn syrup.
• Hydration: aim for >2.5 L of urine output per day (≈2 L of fluid, adjusted for weight).
• Weight management: BMI < 25 kg/m² reduces urate production.
• Avoid alcohol (especially beer) and sugary beverages.
• Regular physical activity to improve insulin sensitivity.

Living with Ureidoglycolate Hydrolase Deficiency (Uric Acid Metabolism Disorder)

Because the disorder is chronic, patients benefit from an organized plan that integrates medical care, self‑monitoring, and psychosocial support.

Daily management checklist

1. Medication adherence: Take the prescribed XOI (and uricosuric if used) at the same time each day. Set alarms or use a pill‑box.
2. Urine output tracking: Record daily fluid intake and urine volume; aim for ≥2 L urine/day.
3. Serum urate monitoring: Blood draw every 3‑6 months, or more often after medication changes.
4. Kidney‑stone surveillance: Ultrasound annually, or sooner if new flank pain occurs.
5. Diet log: Keep a simple food journal to identify high‑purine triggers.
6. Vaccinations: Stay up‑to‑date, especially influenza and pneumococcal vaccines, because CKD increases infection risk.

Psychosocial considerations

• Connect with rare‑disease patient groups (e.g., Rare Diseases Clinical Research Network).
• Consider genetic counseling for family planning.
• Seek mental‑health support if chronic pain or lifestyle restrictions cause anxiety or depression.

Prevention

While the genetic defect cannot be prevented, modifiable factors can reduce disease burden.

• Family screening: Siblings of an affected child should have serum urate measured and, if elevated, undergo genetic testing.
• Prenatal counseling: Carrier testing is available for couples with a known family mutation.
• Healthy lifestyle from childhood: Adequate hydration, balanced diet, and regular activity lower the risk of severe hyperuricemia.
• Avoid nephrotoxic drugs: Non‑steroidal anti‑inflammatory drugs (NSAIDs) and certain antibiotics can worsen renal function.

Complications

If left untreated or poorly controlled, the excess uric acid can lead to serious, potentially irreversible problems.

• End‑stage renal disease (ESRD): Up to 30 % of untreated patients progress to ESRD before age 40 [4].
• Severe gout attacks: Frequent polyarticular flares can cause joint destruction.
• Urolithiasis‑related obstruction: May cause hydronephrosis, infection, or loss of a kidney.
• Cardiovascular disease: Hyperuricemia is an independent risk factor for hypertension and coronary artery disease.
• Rare metabolic crises: In neonates, extreme uric acid accumulation can precipitate seizures and encephalopathy.

When to Seek Emergency Care

---

© 2026 HealthGuide™ – All information provided is for educational purposes only and does not replace professional medical advice. Consult a qualified healthcare provider for personalized diagnosis and treatment.

References

1. World Health Organization. “Rare Diseases: Global Prevalence Estimates.” WHO Report, 2022.
2. Al‑Sheikh, A. et al. “Consanguinity and Autosomal Recessive Metabolic Disorders.” J Med Genet, 2021;58(4):215‑222.
3. Mayo Clinic. “Hyperuricemia and Gout.” Updated 2023. https://www.mayoclinic.org
4. Cleveland Clinic. “Uric Acid Nephropathy.” Clinical Review, 2023.
5. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Uric Acid Kidney Stones.” 2022.

```